Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199

Leukemia

Volumn 28, Issue 6, 2014, Pages 1207-1215

  Khaw, S L ^a,b,c   Merino D ^a,b   Anderson, M A ^a,b,d,e   Glaser, S P ^a,b   Bouillet, P ^a,b   Roberts, A W ^a,b,d,e,f   Huang, D C S ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f VICTORIAN COMPREHENSIVE CANCER CENTRE   (Australia)

Author keywords

ABT 199; ABT 737; apoptosis; BCL2; chronic lymphocytic leukaemia; lymphocyte subsets

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BIM PROTEIN; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; VENETOCLAX; BH3 PROTEIN; NAVITOCLAX; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN MCL 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELL SUSPENSION; CONTROLLED STUDY; CYTOTOXICITY ASSAY; FLOW CYTOMETRY; GRANULOCYTE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LYMPHATIC LEUKEMIA; LYMPHOCYTE SUBPOPULATION; LYMPHOID CELL; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL DEPLETION; THYMOCYTE; TREATMENT DURATION; WESTERN BLOTTING; BONE MARROW CELL; CELL LINEAGE; CHRONIC LYMPHATIC LEUKEMIA; DRUG CYTOTOXICITY; DRUG SENSITIVITY; FETUS; HEMATOPOIETIC CELL; T LYMPHOCYTE SUBPOPULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; B-LYMPHOCYTES; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; BICYCLO COMPOUNDS, HETEROCYCLIC; BLOTTING, WESTERN; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HEALTHY VOLUNTEERS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; MYELOID CELLS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902076004     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.1     Document Type: Article

References (52)

1. Lindsten T, Ross AJ, King A, Zong W, Rathmell JC, Shiels HA et al. The combined functions of proapoptotic Bcl-2 family members Bak and Bax are essential for normal development of multiple tissues. Mol Cell 2000; 6: 1389-1399. (Pubitemid 32045931)
2. Youle RJ, Strasser A. The BCL-2 protein family: Opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47-59.
3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70. (Pubitemid 30046295)
4. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: A link between cancer genetics and chemotherapy. Cell 2002; 108: 153-164. (Pubitemid 34161136)
5. Vousden K, Lane D. p53 in health and disease. Nat Rev Mol Cell Biol 2007; 8: 275-283. (Pubitemid 46474662)
6. Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 2008; 7: 989-1000.
7. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S et al. ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68: 3421-3428.
8. Wilson WH, OConnor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP et al. Navitoclax, a targeted high-Affinity inhibitor of BCL-2, in lymphoid malignancies: A phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010; 11: 1149-1159.
9. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: Results of a phase i study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012; 30: 488-496.
10. Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 2011; 29: 909-916.
11. Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S et al. Programmed anuclear cell death delimits platelet life span. Cell 2007; 128: 1173-1186. (Pubitemid 46427871)
12. Zhang H, Nimmer PM, Tahir SK, Chen J, Fryer RM, Hahn KR et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ 2007; 14: 943-951. (Pubitemid 46655455)
13. Seibler J, Zevnik B, Kuter-Luks B, Andreas S, Kern H, Hennek T et al. Rapid generation of inducible mouse mutants. Nucleic Acids Res 2003; 31: E12.
14. Merino D, Khaw SL, Glaser SP, Anderson DJ, Belmont LD, Wong C et al. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood 2012; 119: 5807-5816.
15. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 2007; 117: 112-121. (Pubitemid 46048458)
16. Rooswinkel RW, van de Kooij B, Verheij M, Borst J. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B. Cell Death Dis 2012; 3: E366.
17. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19: 202-208.
18. Seymour JF, Davids MS, Anderson MA, Kipps TJ, Wierda WG, Pagel JM et al. The BCL-2-specific BH3-mimetic ABT-199 (GDC-0199) is active and well-Tolerated in patients with relapsed/refractory chronic lymphocytic leukemia: Interim results of a Phase I First-in-Human Study. ASH Ann Meet Abstracts 2012; 120: 3923.
19. Davids MS, Roberts AW, Anderson MA, Pagel JM, Kahl BS, Gerecitano JF et al. The BCL-2-specific BH3-mimetic ABT-199 (GDC-0199) is active and well-Tolerated in patients with relapsed non-hodgkin lymphoma: Interim results of a phase I study. ASH Ann Meet Abstracts 2012; 120: 304.
20. Roberts A, Davids M, Mahadevan D, Anderson M, Kipps T, Pagel J et al. Selective inhibition of BCL-2 is active against chronic lymphocytic leukemia (CLL): First clinical experience with the BH3-mimetic ABT-199. Haematologica 2012; 97: 257-258.
21. Motoyama N, Wang FP, Roth KA, Sawa H, Nakayama K, Nakayama K et al. Massive cell death of immature hematopoietic cells and neurons in Bcl-x deficient mice. Science 1995; 267: 1506-1510.
22. Merino R, Ding L, Veis DJ, Korsmeyer SJ, Nuñez G. Developmental regulation of the Bcl-2 protein and susceptibility to cell death in B lymphocytes. EMBO J 1994; 13: 683-691. (Pubitemid 24050683)
23. Grillot DAM, Merino R, Pena JC, Fanslow WC, Finkelman FD, Thompson CB et al. Bcl-x exhibits regulated expression during B cell development and activation and modulates lymphocyte survival in transgenic mice. J Exp Med 1996; 183: 381-391.
24. Veis DJ, Sorenson CM, Shutter JR, Korsmeyer SJ. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 1993; 75: 229-240. (Pubitemid 23320287)
25. Veis DJ, Sentman CL, Bach EA, Korsmeyer SJ. Expression of the Bcl-2 protein in murine and human thymocytes and in peripheral T lymphocytes. J Immunol 1993; 151: 2546-2554. (Pubitemid 23264507)
26. Nakayama K, Nakayama K-I, Negishi I, Kuida K, Sawa H, Loh DY. Targeted disruption of bcl-2ab in mice: Occurrence of gray hair, polycystic kidney disease, and lymphocytopenia. Proc Natl Acad Sci USA 1994; 91: 3700-3704.
27. Matsuzaki Y, Nakayama K-I, Nakayama K, Tomita T, Isoda M, Loh DY et al. Role of bcl-2 in the development of lymphoid cells from the hematopoietic stem cell. Blood 1997; 89: 853-862. (Pubitemid 27121278)
28. Gratiot-Deans J, Ding L, Turka LA, Nuñez G. bcl-2 proto-oncogene expression during human T cell development. J Immunol 1993; 151: 83-91. (Pubitemid 23206973)
29. Gratiot-Deans J, Merino R, Nuñez G, Turka LA. Bcl-2 expression during T-cell development: Early loss and late return occur at specific stages of commitment to differentiation and survival. Proc Natl Acad Sci USA 1994; 91: 10685-10689.
30. Ma A, Pena JC, Chang B, Margosian E, Davidson L, Alt FW et al. Bclx regulates the survival of double-positive thymocytes. Proc Natl Acad Sci USA 1995; 92: 4763-4767.
31. Green DR, Walczak H. Apoptosis therapy: Driving cancers down the road to ruin. Nat Med 2013; 19: 131-133.
32. Davids MS, Letai A. ABT-199: Taking dead aim at BCL-2. Cancer Cell 2013; 23: 139-141.
33. Bouillet P, Metcalf D, Huang DCS, Tarlinton DM, Kay TWH, Köntgen F et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999; 286: 1735-1738. (Pubitemid 129515880)
34. Villunger A, Michalak EM, Coultas L, Müllauer F, Böck G, Ausserlechner MJ et al. p53-And drug-induced apoptotic responses mediated by BH3-only proteins Puma and Noxa. Science 2003; 302: 1036-1038. (Pubitemid 37386194)
35. Knudson CM, Tung KSK, Tourtellotte WG, Brown GAJ, Korsmeyer SJ. Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science 1995; 270: 96-99.
36. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985; 318: 533-538. (Pubitemid 16173038)
37. Glaser SP, Lee EF, Trounson E, Bouillet P, Wei A, Fairlie WD et al. Anti-Apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev 2012; 26: 120-125.
38. Mason KD, Khaw SL, Rayeroux KC, Chew E, Lee EF, Fairlie WD et al. The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia 2009; 23: 2034-2041.
39. OReilly LA, Print C, Hausmann G, Moriishi K, Cory S, Huang DCS et al. Tissue expression and subcellular localization of the pro-survival molecule Bcl-w. Cell Death Differ 2001; 8: 486-494.
40. Certo M, Moore Vdel G, Nishino M, Wei G, Korsmeyer S, Armstrong SA et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006; 9: 351-365. (Pubitemid 43668734)
41. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI et al. Pro-Apoptotic Bak is sequestered by Mc1-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005; 19: 1294-1305. (Pubitemid 41003019)
42. Labi V, Erlacher M, Kiessling S, Manzl C, Frenzel A, OReilly L et al. Loss of the BH3-only protein Bmf impairs B cell homeostasis and accelerates gamma irradiationinduced thymic lymphoma development. J Exp Med 2008; 205: 641-655. (Pubitemid 351439310)
43. Erlacher M, Laabi V, Manzl C, Bock G, Tzankov A, Haecker G et al. Puma cooperates with Bim, the rate-limiting BH3-only protein in cell death during lymphocyte development, in apoptosis induction. J Exp Med 2006; 203: 2939-2951. (Pubitemid 46026171)
44. Alves NL, Derks IA, Berk E, Spijker R, van Lier RA, Eldering E. The Noxa/Mcl-1 axis regulates susceptibility to apoptosis under glucose limitation in dividing T cells. Immunity 2006; 24: 703-716. (Pubitemid 43867360)
45. Vandenberg CJ, Cory S. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood 2013; 121: 2285-2288.
46. Hallaert DY, Jaspers A, van Noesel CJ, van Oers MH, Kater AP, Eldering E. c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: Implications for therapeutic targeting of chemoresistant niches. Blood 2008; 112: 5141-5149.
47. Soderquist R, Bates DJ, Danilov AV, Eastman A. Gossypol overcomes stroma-mediated resistance to the BCL2 inhibitor ABT-737 in chronic lymphocytic leukemia cells ex vivo. Leukemia 2013; 27: 2262-2264.
48. Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012; 30: 3460-3467.
49. Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012; 30: 3452-3459.
50. Touzeau C, Dousset C, Le Gouill S, Sampath D, Leverson JD, Souers AJ et al. The Bcl-2 specific BH3 mimetic ABT-199: A promising targeted therapy for t(11;14) multiple myeloma. Leukemia 2014; 28: 210-212.
51. Lock R, Carol H, Houghton PJ, Morton CL, Kolb EA, Gorlick R et al. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer 2008; 50: 1181-1189. (Pubitemid 351555542)
52. Khaw SL, Huang DC, Roberts AW. Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies. Pathology 2011; 43: 525-535.